# Zhongke Weizhen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zhongke-weizhen

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.casmn.com
- Total disclosed funding: $2.9M
- Latest round: Angel (Oct 1, 2018)
- Investors on record: 2

## About

Founded in 2018 and based in Beijing, China, Zhongke Weizhen operates as a medical company that focuses on the research and development of microneedle transdermal drug delivery technologies. It was recognized as the National High-tech Enterprise. The company has a branch office in Chongqing. Lin Jiang, the general manager of the company, graduated from the Institute of Physical and Chemical Technology of the Chinese Academy of Sciences and worked for BYD, Yuntianhua, and other companies. The company completed the construction of the Post-doctoral workstation in 2023. In April 2020, Zhongke Weizhen closed a pre-series A funding from other unspecified investors.

Zhongke Weizhen mainly engages in the research, development, production, and sales of polymer microneedle technology as well as innovative transdermal technology. Its business includes the research, development, and production of microneedle transdermal drug delivery technology, medical devices, and cosmetics. The product pipeline can be categorized into metabolic, Anesthesia, oncology, Central Nervous System, and other series. Products can be used in pharmaceutical companies and the medical aesthetic industry.

The company generates revenue by providing microneedle transdermal drug delivery technologies and related products.

## Funding rounds

- Angel, Oct 1, 2018, $2.9M — Casstar Capital, CAS Venture Capital

## Investors

- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel
- CAS Venture Capital (https://capitalatlas.ai/funds/cas-venture-capital) — Angel